Navigation Links
New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes
Date:11/21/2008

FRANKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Today, prescription drugs are the first choice for medical intervention in treating 88 percent of patients suffering chronic conditions. The 50 percent of Americans treated for a chronic condition account for 96 percent of all prescription drug spending and 75 percent of all medical costs. A proprietary new pharmacy model developed over three years by Medco Health Solutions, Inc. (NYSE: MHS) significantly reduces critical gaps in care for patients with chronic and complex diseases and lowers overall medical costs, according to an independently validated set of analyses released today.

"The data could not be more compelling. In an era where we have seen huge increases in the number of patients with chronic disease, an evidence-based protocol model leveraging the Medco Therapeutic Resource Centers(R), has proven critical to improving the effectiveness of treatment and driving down the cost of health care. We've invented an end-to-end capability that yields better outcomes, both clinically and financially," said Medco's Chairman and Chief Executive Officer, David B. Snow Jr.

Rigorous large-scale analyses were conducted by Medco, and the associated clinical content and general analytical processes were independently reviewed and validated by the actuarial and consulting firm, Milliman Inc.

The first analysis evaluated 600,000 patients to identify gaps in care in their treatment of diabetes, and pulmonary and heart disease. The gaps in care ranged from deviations in nationally accepted clinical protocols, including incorrect and over-prescribing, to patients failing to appropriately follow their physician's instructions.

Key findings over a 90-day study period:

  • For hypertension, Medco closed 81
    '/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
2. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
3. Shining light on sciences dark data: New venture ensures a fuller scientific record
4. New Government Data: Mail-Service Pharmacies Grow, But Public Programs Lag Behind
5. Five Hospitals to Share Patient Data: ICW Connects Regional Medical Centers and University Facility
6. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
7. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
8. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
9. Advanced lung cancer patients see improved, progression-free survival
10. Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures
11. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... 2014 Parker Waichman LLP, a national ... comments on a recent tobacco lawsuit in which a ... billion in punitive damages. Cynthia Robinson brought the lawsuit ... case is Cynthia Robinson v. R.J. Reynolds Tobacco Company ... Circuit Court, Escambia County, Florida; Case Number 2008 CA ...
(Date:7/25/2014)... nearly 27,000 older adults on five continents found that ... on a simple test that measures how fast people ... tested positive for pre-dementia were twice as likely as ... led by scientists at Albert Einstein College of ... Center , was published online on July 16, 2014 ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As thousands ... in U.S. courts, Bernstein Liebhard LLP notes that the ... by the consumer advocacy group, Public Citizen, to order ... a letter dated May 1, 2014, and released to ... group’s petition for a ban on the marketing of ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4
... may be at increased risk of experiencing a life-threatening ... with low POD had significantly more emergency department visits, ... 2 year study period than those with normal dyspnoea ... to be older, female and generally had suffered from ...
... well perceived that smoking accelerates the risk of heart disease, ... capacity for the development of a heart attack.This is because ... immediate impact on the cardiovascular system.// ,In a study ... smoked a cigarette within six hours of developing symptoms had ...
... Johns Hopkins University School of Medicine have recently found that ... brain that lets us stop smelling something, even though the ... recent issue of the journal Science show that a protein ... main job of these reurons is to detect smells and ...
... bring to notice that sensible drinking could reduce their risk ... of excess. In a new leaflet, the Stroke Association says ... caused by blood clots blocking arteries - which account for ... ,Alcohol thins the blood, so can prevents the formation ...
... a leafy plant native to the South Sea Islands. It ... cases of liver diseases. The herb is commonly used by ... stress and muscle spasms. According to experts, the herb behaves ... not chemically related. ,Benzodiazepines have been shown to be ...
... first isolated a decade ago at Johns Hopkins, may ... study shows that the compound, sulphoraphane, helps cells defend ... and toxic molecules called oxidants.// , Unlike standard anti-oxidants ... combat, broccoli’s compound is a covert operative that works ...
Cached Medicine News:
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
... StressVue puts leading-edge stress testing within reach ... or clinic to the most advanced cardiology ... flat panel monitor with options for a ... printer for continuous printing. StressVue is designed ...
... Philip's EASITrak 12 gives you the ... informed treatment decisions for your patients with ... ,Designed with the EASI Lead System, this ... leads to capture a derived 12-lead ECG. ...
A component of the 3M Littmann Electronic Stethoscope Model 4000...
... monitor captures the data you need while ... only five electrodes, the DigiTrak Plus provides ... patient test, which can be up to ... Three channels of ECG recording and a ...
Medicine Products: